Evaluation of Bacterial Polysaccharide Immune Globulin for the Treatment or Prevention of Haemophilus influenzae Type b and Pneumococcal Disease
- 1 June 1992
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 165 (Supplement) , S129-S133
- https://doi.org/10.1093/infdis/165-supplement_1-s129
Abstract
A human hyperimmune globulin termed bacterial polysaccharide immune globulin (BPIG) has been prepared from plasma donors immunized with Haemophilus influenzae type b (Rib), pneumococcal, and meningococcal vaccines. At a dose of 0.5 ml/kg, BPIG increased levels of antibody to Rib by > 0.15 μg/ml within 4–6 h and by 2–4 μg/ml at 72 h. Thereafter, antibody declined, with a mean half-life of 27 days. BPIG treatment of Apache infants did not impair their active antibody responses to concurrently administered diphtheria-tetanus-pertussis or Rib oligosaccharide- diptheria CRM197 conjugate vaccines. In high-risk Apache infants, BPIG given at 2, 6, and 10 months of age provided significant protection from invasive Rib infection during infancy. Thus, BPIG may have utility in the prevention of Rib infections in high-risk patients who cannot be immunized adequately with Rib conjugate vaccines.Keywords
This publication has 0 references indexed in Scilit: